Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNimesulide
Description: Cyclooxygenase-2 (COX-2) inhibitor
Alternative Names: Flogovital,Aulin
Chemical Name: N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide
Purity: ≥99% (HPLC)
Biological Activity for Nimesulide
Nimesulide is a selective, orally active cyclooxygenase-2 (COX-2) inhibitor. Produces potent analgesic, anti-inflammatory and antipyretic activities in vivo. Reported to produce fewer gastrointestinal side effects than standard NSAIDs. Also inhibits sodium-dependent neutral amino acid transporter B0AT1 (SLC6A19; IC50 = 23 μM).
Technical Data for Nimesulide
| M. Wt | 308.31 |
| Formula | C13H12N2O5S |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 51803-78-2 |
| PubChem ID | 4495 |
| InChI Key | HYWYRSMBCFDLJT-UHFFFAOYSA-N |
| Smiles | CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Nimesulide
References for Nimesulide
References are publications that support the biological activity of the product.
Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437 PMID: 9427063
Cullen et al (1998) Selective cyclooxygenase-2 inhibition by nimesulide in man. J.Pharmacol.Exp.Ther. 287 578 PMID: 9808683
Pochini et al (2014) Nimesulide binding site in the B0AT1 (SLC6A19) amino acid transporter. Mechanism of inhibition revealed by proteoliposome transport assay and molecular modelling. Biochem.Pharmacol. 89 422 PMID: 24704252
View Related Products by Target
View Related Products by Product Action
Keywords: Nimesulide, Nimesulide supplier, Cyclooxygenase-2, COX-2, inhibitors, inhibits, Cyclooxygenase, Oxygenases, Oxidases, B0AT1, SLC6A19, sodium-dependent, neutral, amino, acid, transporter, Flogovital, Aulin, Other, Ion, Pumps/Transporters, 2470, Tocris Bioscience
3 Citations for Nimesulide
Citations are publications that use Tocris products. Selected citations for Nimesulide include:
Baranowska-Kuczko et al (2014) Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. J Neuroimmune Pharmacol 387 477 PMID: 24682422
Anneken et al (2013) MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase. Nat Commun 8 58 PMID: 23179355
Staniaszek et al (2010) Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. Br J Pharmacol 160 669 PMID: 20590570
Reviews for Nimesulide
There are currently no reviews for this product. Be the first to review Nimesulide and earn rewards!
Have you used Nimesulide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.